Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
(FAVORIT Trial)
Recruiting in Palo Alto (17 mi)
+29 other locations
MA
Overseen byMyra A Carpenter, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2 & 3
Waitlist Available
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
Research Team
AL
Andrew Levey, M.D.
Principal Investigator
Tufts Medical Center
MA
Myra A Carpenter, PhD
Principal Investigator
University of North Carolina, Chapel Hill
Eligibility Criteria
Inclusion Criteria
35 - 75 years old
Had kidney transplant at least 6 months
Calculated Creatinine Clearance must be 25 mL/min or greater
See 1 more
Treatment Details
Interventions
- High Dose Multivitamin (Multivitamin)
- Low Dose Multivitamin (Multivitamin)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: High Dose MultivitaminExperimental Treatment1 Intervention
Multivitamin with increased folic acid, vitamin B6 and vitamin B12
Group II: Low Dose MultivitaminActive Control1 Intervention
Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Northwestern UniversityChicago, IL
Mayo ClinicRochester, MN
University of Iowa Hospitals and ClinicsIowa City, IA
University of California at San FranciscoSan Francisco, CA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lead Sponsor
Trials
2513
Patients Recruited
4,366,000+
Office of Dietary Supplements (ODS)
Collaborator
Trials
55
Patients Recruited
54,500+